ADAMTS13 and thrombotic thrombocytopenic purpura: Although the clinical signs of TTP, such as fever, impaired consciousness, hemolytic anemia, and thrombocytopenia, improved after the initiation of treatment, the ADAMTS13 inhibitor persisted, and ADAMTS13 activity remained suppressed.